-transparent.png){kind=logo}
HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels. Blood and tissue 6-8 hr. after oral administration. The concentration of 5-FU in tissue was almost in the effective levels. In addition, the 5-FU level in the tissue of hepatocellular carcinoma tended to be higher than in non cancerous portion of the liver. 5-FU tissue concentration was not correlated with various laboratory data for the liver function (K-ICG, T. bil, GOT, GPT, etc.) From these results, it is suggested that HCFU is a useful anticancer agent for hepatocellular carcinoma especially for the cases accompanied liver cirrhosis.
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
October 1985,
Nihon Gan Chiryo Gakkai shi,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
May 1988,
Gan no rinsho. Japan journal of cancer clinics,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
May 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
November 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
December 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
January 2000,
Anticancer research,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
September 1992,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
August 1989,
European journal of cancer & clinical oncology,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
October 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Mori, and
K Hamazaki, and
H Mimura, and
K Orita
January 2001,
Anticancer research,
